Published peptide research references
Teriparatide
Governed registry record
25 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
Open the peptide evidence profile →Approved source records
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.
Charlotte Beaudart, Nicola Veronese, Jonathan Douxfils, Jotheeswaran Amuthavalli Thiyagarajan, Francesco Bolzetta, Paolo Albanese, Gianpaolo Voltan, Majed Alokail, Nicholas C Harvey, Nicholas R Fuggle, Olivier Bruyère, René Rizzoli · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.
Mingnian Li, Zhuoqi Ge, Benqi Zhang, Li Sun, Zhongyuan Wang, Tao Zou, Qi Chen · Archives of osteoporosis · 2024
Biosimilarity Assessment of the Biosimilar Teriparatide Candidate and the Reference Drug in Healthy Subjects.
Xuan Wang, Xintong Liang, Tenghua Wang, Yaoxuan Zhan, Haiyan Liu, Chen Li, Xianbo Li, Hui Ma, Zhiqin Hu, Xiaole Wang, Shuangshuang Xiao, Li Ban · Clinical pharmacology in drug development · 2023
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Chelsea Ayers, Devan Kansagara, Brittany Lazur, Rongwei Fu, Amy Kwon, Curtis Harrod · Annals of internal medicine · 2023
Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.
Satoshi Mori, Hiroshi Hagino, Toshitsugu Sugimoto, Shiro Tanaka, Yuji Mitomo, Kaito Takahashi, Teruki Sone, Toshitaka Nakamura, Satoshi Soen · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023
Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study.
Ko Chiba, Narihiro Okazaki, Ayako Kurogi, Tsuyoshi Watanabe, Ai Mori, Nobuhiko Suzuki, Koichi Adachi, Makoto Era, Kazuaki Yokota, Takuma Inoue, Yoshihiro Yabe, Keizo Furukawa · Bone · 2022
Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial.
J W Nieves, F Cosman, D McMahon, M Redko, I Hentschel, R Bartolotta, M Loftus, J J Kazam, J Rotman, J Lane · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
Teriparatide treatment in severe osteoporosis - a controlled 10-year follow-up study.
Georgios Kontogeorgos, Emily Krantz, Penelope Trimpou, Christine M Laine, Kerstin Landin-Wilhelmsen · BMC musculoskeletal disorders · 2022
Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Sarah Davis, Emma Simpson, Jean Hamilton, Marrissa Martyn-St James, Andrew Rawdin, Ruth Wong, Edward Goka, Neil Gittoes, Peter Selby · Health technology assessment (Winchester, England) · 2020
Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial.
Felicia Cosman, Donald McMahon, David Dempster, Jeri W Nieves · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2020
Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.
Ie-Wen Sim, Gelsomina L Borromeo, Claudine Tsao, Rita Hardiman, Michael S Hofman, Christian Papatziamos Hjelle, Musib Siddique, Gary J R Cook, John F Seymour, Peter R Ebeling · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
Houchen Lyu, Sizheng S Zhao, Kazuki Yoshida, Sara K Tedeschi, Chang Xu, Sagar U Nigwekar, Benjamin Z Leder, Daniel H Solomon · The Journal of clinical endocrinology and metabolism · 2019
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
David L Kendler, Fernando Marin, Cristiano A F Zerbini, Luis A Russo, Susan L Greenspan, Vit Zikan, Alicia Bagur, Jorge Malouf-Sierra, Péter Lakatos, Astrid Fahrleitner-Pammer, Eric Lespessailles, Salvatore Minisola · Lancet (London, England) · 2018
Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study.
J N Tsai, S M Burnett-Bowie, H Lee, B Z Leder · Bone · 2017
Relative bioavailability between two teriparatide formulations in healthy volunteers.
Javier Farías, Guillermo A Keller, Mariana Papouchado, María C Villa Etchegoyen, Marcelo E Criscuolo, Roberto A Diez, Guillermo Di Girolamo · International journal of clinical pharmacology and therapeutics · 2016
Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.
Atsushi Nishikawa, Takehiro Ishida, Masanori Taketsuna, Fumito Yoshiki, Hiroyuki Enomoto · Clinical interventions in aging · 2016
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Benjamin Z Leder, Joy N Tsai, Alexander V Uihlein, Paul M Wallace, Hang Lee, Robert M Neer, Sherri-Ann M Burnett-Bowie · Lancet (London, England) · 2015
Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
N C Harvey, J A Kanis, A Odén, T Nakamura, M Shiraki, T Sugimoto, T Kuroda, H Johansson, E V McCloskey · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015
FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
N C Harvey, J A Kanis, A Odén, R T Burge, B H Mitlak, H Johansson, E V McCloskey · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Benjamin Z Leder, Joy N Tsai, Alexander V Uihlein, Sherri-Ann M Burnett-Bowie, Yuli Zhu, Katelyn Foley, Hang Lee, Robert M Neer · The Journal of clinical endocrinology and metabolism · 2014
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.
Joy N Tsai, Alexander V Uihlein, Hang Lee, Ruchit Kumbhani, Erica Siwila-Sackman, Elizabeth A McKay, Sherri-Ann M Burnett-Bowie, Robert M Neer, Benjamin Z Leder · Lancet (London, England) · 2013
Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
J H Krege, X Wan · Bone · 2012
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Kenneth G Saag, Elizabeth Shane, Steven Boonen, Fernando Marín, David W Donley, Kathleen A Taylor, Gail P Dalsky, Robert Marcus · The New England journal of medicine · 2007
Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures.
J Christopher Gallagher, Harry K Genant, Gerald G Crans, Socorro Juan Vargas, John H Krege · The Journal of clinical endocrinology and metabolism · 2005
Teriparatide (forteo) for osteoporsis.
The Medical letter on drugs and therapeutics · 2003